###### Strengths and limitations of this study

-   This is the first Japanese study to describe outpatient antibiotic prescription patterns linked to individual diagnosis data, comprehensively, by use of the public health insurance claims database.

-   This study included patients \>65 years of age, who have not typically been included in previous Japanese studies.

-   The accuracy of the diagnosis has not been validated due to the nature of the administrative claims database.

-   There are some unmeasured potential confounding factors such as out-of-hours visits and physician specialty.

Introduction {#s1}
============

There is a growing concern about antimicrobial-resistant bacterial infections. Antimicrobial resistance results in increased healthcare costs, prolonged hospitalisation and death.[@R1] The WHO launched the global action plan to combat the antimicrobial-resistant bacteria in 2015[@R4] and requested Member States to endorse national action plans within 2 years. The government of Japan launched a national action plan in 2016 in response to the request.[@R5]

Since antimicrobial use is one of the important factors in the emergence of antimicrobial resistance,[@R6] it is essential to reduce the inappropriate use of antibiotics. In Japan, a previous sales data-based study revealed that oral antibiotics account for \>90% of total antibiotic consumption and that broad-spectrum antibiotics (third-generation cephalosporins, macrolides and fluoroquinolones) account for 77% of oral antibiotic consumption (daily doses defined per 1000 inhabitants per day).[@R7] The Japanese national action plan aims to reduce the total antimicrobial use to two-thirds of current use, and the use of oral cephalosporins, quinolones and macrolides to one-half, by 2020. To reduce inappropriate antimicrobial use, it is important to determine the antimicrobial prescribing patterns and factors associated with antibiotic prescription. However, such information has been limited in Japan to date. Although a few recent studies[@R8] described the prescription patterns for upper respiratory tract infections and bronchitis, the prescription patterns of infections other than acute respiratory tract infections (ARTIs) have not been clarified. In addition, patients \>65 years of age have not been commonly included in these studies, because these studies relied on data from an employee-based insurance claims database. With the high rate in ageing population in Japan, it is important to describe the prescription patterns in elderly patients.

In this study, we described outpatient oral antibiotic prescribing patterns for all infections and in all ages using the Japanese administrative claims database. Furthermore, we aimed to identify factors associated with antibiotic prescriptions for ARTIs and gastrointestinal infections, the targets of the antimicrobial stewardship guideline formulated by the government of Japan in 2017.[@R10]

Methods {#s2}
=======

Data sources {#s2a}
------------

The current population of Japan is approximately 127 million. All citizens are enrolled in a universal health coverage insurance programme provided by the social insurance system (for employees \<75 years of age), national health insurance system (for self-employed or unemployed people \<75 years of age) and the late elders' health insurance system (for those aged ≥75 years). In Japan, patients can visit any clinic of their choice. All physicians working at any free-standing or hospital-based clinics can provide primary care and prescribe antibiotics.

We conducted a retrospective analysis using the administrative health insurance claims database of Kumamoto prefecture, situated in the southwestern region of Japan, with a population of about 1.7 million. This database covers approximately 780 000 residents of Kumamoto prefecture (44% of the population) who were beneficiaries of the national health insurance system[@R11] or the late elders' health insurance system.[@R12] The participants in this study may be older than the general population of Japan.

The database is composed of medical and pharmacy claims. It provides monthly information about patient demographics (year and month of birth and sex), diagnoses, date of diagnoses, medical procedures, medications, scale (number of beds) of the medical facility, as well as the identification numbers assigned to each individual, medical facility and dispensing pharmacy. At the end of each month, claims are registered from each medical facility. The diagnoses were recorded by physicians of each medical facility and coded according to the International Classification of Diseases and Related Health Problems, 10th Revision (ICD-10).

Data preparation {#s2b}
----------------

We linked the medical and pharmacy claims on the database using an identification number unique to each patient, medical facility and dispensing pharmacy. We identified all newly diagnosed outpatients, with any infectious diseases, between April 2012 and March 2013. Infectious diseases diagnoses were categorised according to the indication for antibiotic use (online [supplementary table S1](#SP1){ref-type="supplementary-material"}, available as online [supplementary data](#SP1){ref-type="supplementary-material"}). This categorization was based on the study by Fleming-Dutra *et al*.[@R13] Bronchitis and bronchiolitis were divided into two categories based on whether the patients had chronic obstructive pulmonary disease (COPD) as comorbidity or not, because of differing need of treatment with antibiotics. If a patient had multiple infectious diagnoses in 1 month, a single infectious diagnosis, selected in order from group 1 (antibiotics are usually indicated) to group 3 (antibiotics are rarely indicated), and the first-listed diagnosis in alphabetical order of ICD-10 codes in the selected group was included in the analyses (online [supplementary table S1](#SP1){ref-type="supplementary-material"}).
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We also identified all outpatients with any antibiotic prescriptions. Topical, intramuscular and intravenous antibiotics were excluded. Antibiotics were categorised according to the Anatomical Therapeutic Chemical (ATC) classification system (<http://www.whocc.no/atcddd/>) as follows: tetracyclines (J01A), penicillins (J01C), first-generation and second-generation cephalosporins (J01DB and J01DC), third-generation cephalosporins (J01DD), sulfonamides and trimethoprim (J01E), macrolides (J01FA), quinolones (J01M) and others (J01B, J01DH, J01DI, J01FF, J01G and J01X). We assumed that third-generation cephalosporins accounted for most of cephalosporins used in Japan; hence, we divided cephalosporins into two groups: first/second-generation and third-generation cephalosporins. Antibiotics were linked to the infectious diagnoses in each patient's claims when both the code of antibiotics and the code of diagnoses were recorded in the same month.

Data analysis {#s2c}
-------------

We calculated the frequency of antibiotic prescription for all visits with infections (according to diagnosis and antibiotic class). For ARTIs (including pharyngitis, sinusitis, bronchitis/bronchiolitis and viral upper respiratory infections \[URI\]) and gastrointestinal infections, we performed separate multivariable logistic regression analyses to identify the factors associated with antibiotic prescriptions. The variables were as follows: age and sex of patients and scale (number of beds) of the medical facilities. Generalised estimating equations with exchangeable correlation structure were used to account for the clustering of the medical facilities. P values \<0.05 were considered statistically significant. All statistical analyses were performed with the statistical package R, V.3.5.0 (<http://cran.r-project.org>).

Patient involvement {#s2d}
-------------------

No patients were involved in the development of the research question or the outcome measures, nor were they involved in developing plans for design or implementation of the study. No patients were asked for advice regarding the interpretation or writing of results. There are no plans to disseminate the study results to the relevant patient community.

Results {#s3}
=======

In total, there were 7 770 481 outpatient visits between April 2012 and March 2013. Antibiotics were prescribed in 682 822 visits (860 antibiotic prescriptions per 1000 population). Among these, third-generation cephalosporins were the most frequently prescribed (237 372 visits, 35%), followed by macrolides (215 656 visits, 32%) and quinolones (145 135 visits, 21%). This trend was observed regardless of age group ([table 1](#T1){ref-type="table"}) and scale of the medical facility ([table 2](#T2){ref-type="table"}), except for those \<9 years of age in whom the systemic use of quinolones is not recommended. Information about facility scale was available from 669 086 out of 682 822 visits. Of these, antibiotics were prescribed most frequently at free-standing clinics (530 916 visits, 79%), followed by small-scale (\<200 beds; 78 546 visits, 12%), medium-scale (200--499 beds; 45 271 visits, 7%) and large-scale (≥500 beds; 14 353 visits, 2%) hospital-based clinics ([table 2](#T2){ref-type="table"}).

###### 

Frequency of oral antibiotic prescriptions by age and antibiotic groups

  Antibiotic groups coded by ATC classification\*   Number (%) of visits with antibiotic prescription                                                    
  ------------------------------------------------- --------------------------------------------------- --------------- --------------- ---------------- ----------------
  Penicillins                                       7495 (7.2)                                          1724 (4.2)      8574 (4.5)      14 924 (4.3)     32 717 (4.8)
  First/second-generation cephalosporins            964 (0.9)                                           411 (1.0)       2987 (1.6)      5719 (1.6)       10 081 (1.5)
  Third-generation cephalosporins                   52 082 (49.9)                                       16 367 (40.1)   60 621 (31.8)   108 302 (31.2)   237 372 (34.8)
  Macrolides                                        28 597 (27.4)                                       14 691 (36.0)   56 719 (29.7)   115 649 (33.3)   215 656 (31.6)
  Quinolones                                        7286 (7.0)                                          4158 (10.2)     48 843 (25.6)   84 848 (24.4)    145 135 (21.3)
  Sulfonamides and trimethoprim                     32 (0.0)                                            53 (0.1)        1389 (0.7)      4520 (1.3)       5994 (0.9)
  Tetracyclines                                     915 (0.9)                                           1366 (3.3)      4366 (2.3)      5147 (1.5)       11 794 (1.7)
  Other antibiotics                                 6901 (6.6)                                          2021 (5.0)      7186 (3.8)      7965 (2.3)       24 073 (3.5)
  All antibiotics                                   104 272                                             40 791          190 685         347 074          682 822

\*Penicillins, J01C; First-generation cephalosporins, J01DB; Second-generation cephalosporins, J01DC; Third-generation cephalosporins, J01DD; Macrolides, J01FA; Quinolones, J01M; Sulfonamides and trimethoprim, J01E; Tetracyclines, J01A; Other antibiotics, J01B, J01DH, J01DI, J01FF, J01G and J01X.

ATC, anatomical therapeutic chemical.

###### 

Frequency of oral antibiotic prescriptions by facility scale and antibiotic group\*

  Antibiotic groups coded by ATC classification†   Number (%) of visits with antibiotic prescription                                                 
  ------------------------------------------------ --------------------------------------------------- --------------- --------------- ------------- ----------------
  Penicillins                                      25 225 (4.8)                                        3453 (4.4)      2968 (6.6)      565 (3.9)     32 211 (4.8)
  First/second-generation cephalosporins           6755 (1.3)                                          1789 (2.3)      1245 (2.8)      158 (1.1)     9947 (1.5)
  Third-generation cephalosporins                  187 928 (35.4)                                      25 463 (32.4)   15 252 (33.7)   4139 (28.8)   232 782 (34.8)
  Macrolides                                       169 980 (32.0)                                      26 307 (33.5)   11 319 (25.0)   3833 (26.7)   211 439 (31.6)
  Quinolones                                       110 770 (20.9)                                      17 877 (22.8)   9992 (22.1)     3402 (23.7)   142 041 (21.2)
  Sulfonamides and trimethoprim                    712 (0.1)                                           1069 (1.4)      2234 (4.9)      1618 (11.3)   5633 (0.8)
  Tetracyclines                                    9477 (1.8)                                          846 (1.1)       803 (1.8)       320 (2.2)     11 446 (1.7)
  Other antibiotics                                20 069 (3.8)                                        1742 (2.2)      1458 (3.2)      318 (2.2)     23 587 (3.5)
  All antibiotics                                  5 30 916                                            78 546          45 271          14 353        669 086

\*13 736 patients with antibiotic prescription were excluded due to missing data about facility scale.

†Penicillins, J01C; First-generation cephalosporins, J01DB; Second-generation cephalosporins, J01DC; Third-generation cephalosporins, J01DD; Macrolides, J01FA; Quinolones, J01M; Sulfonamides and trimethoprim, J01E; Tetracyclines, J01A; Other antibiotics, J01B, J01DH, J01DI, J01FF, J01G and J01X.

ATC, anatomical therapeutic chemical.

We were able to link the individual diagnoses to the antibiotic prescription in 4 47 232 visits ([table 3](#T3){ref-type="table"}). Of these patients, approximately 60% of antibiotics were prescribed for ARTIs, including viral URI (96 989 visits, 22%), pharyngitis (78 469 visits, 18%), bronchitis without COPD (47 248 visits, 11%) and sinusitis (45 456 visits, 10%). Other than ARTIs, there were frequent antibiotic prescriptions for gastrointestinal infections (41 309 visits, 9%), urinary tract infections (37 674 visits, 8%), and skin, cutaneous and mucosal infections (23 572 visits, 5%). The antibiotic prescription rates for viral URI, pharyngitis, bronchitis (without underlying COPD), sinusitis and gastrointestinal infections were 35% (96 989 out of 274 441 visits), 54% (78 469 out of 146 508 visits), 53% (47 248 out of 89 479 visits), 57% (45 456 out of 80 078 visits) and 30% (41 309 out of 137 661 visits), respectively ([table 3](#T3){ref-type="table"}).

###### 

Frequency of oral antibiotic prescriptions by antibiotic groups and diagnoses

  Diagnoses                            All visits   Visits with any antibiotic prescription and prescription rate (%)   Number (%) of visits with antibiotic prescriptions by antibiotic groups\*                                                                                          
  ------------------------------------ ------------ ------------------------------------------------------------------- --------------------------------------------------------------------------- ------------ --------------- --------------- --------------- ----------- ------------- -------------
  Miscellaneous bacterial infections   45 061       20 429 (45.3)                                                       2969 (11.5)                                                                 468 (1.8)    7404 (28.7)     7868 (30.5)     5731 (22.2)     181 (0.7)   444 (1.7)     728 (2.8)
  STD                                  14 051       3931 (28.0)                                                         86 (1.9)                                                                    76 (1.7)     836 (18.9)      1515 (34.2)     496 (11.2)      14 (0.3)    147 (3.3)     1260 (28.4)
  Bacterial pneumonia                  47 035       21 473 (45.7)                                                       916 (3.4)                                                                   121 (0.5)    5044 (18.9)     8568 (32.2)     11 236 (42.2)   191 (0.7)   238 (0.9)     316 (1.2)
  Abdominal infection                  9208         2077 (22.6)                                                         69 (3.2)                                                                    29 (1.3)     680 (31.1)      142 (6.5)       1086 (49.7)     ≤10         ≤10           177 (8.1)
  Orthopaedic infection                1749         380 (21.7)                                                          36 (8.2)                                                                    22 (5.0)     225 (51.4)      21 (4.8)        93 (21.2)       ≤10         19 (4.3)      22 (5.0)
  Urinary tract infections             97 948       37 674 (38.5)                                                       1195 (2.9)                                                                  567 (1.4)    14 735 (36.0)   1998 (4.9)      20 229 (49.5)   429 (1.0)   521 (1.3)     1232 (3.0)
  PID                                  11 621       1763 (15.2)                                                         84 (4.6)                                                                    26 (1.4)     1127 (61.2)     164 (8.9)       167 (9.1)       ≤10         ≤10           273 (14.8)
  GI infections                        1 37 661     41 309 (30.0)                                                       2121 (4.6)                                                                  264 (0.6)    12 060 (26.0)   8603 (18.6)     13 206 (28.5)   196 (0.4)   232 (0.5)     9680 (20.9)
  Skin infections                      62 202       23 572 (37.9)                                                       1167 (4.6)                                                                  1337 (5.3)   15 311 (60.6)   1975 (7.8)      2848 (11.3)     25 (0.1)    997 (3.9)     1615 (6.4)
  Suppurative otitis media             16 059       9958 (62.0)                                                         1566 (11.8)                                                                 18 (0.1)     5213 (39.1)     1972 (14.8)     3654 (27.4)     ≤10         92 (0.7)      812 (6.1)
  Pharyngitis                          1 46 508     78 469 (53.6)                                                       4372 (5.1)                                                                  450 (0.5)    35 958 (41.8)   27 454 (31.9)   16 387 (19.1)   121 (0.1)   301 (0.3)     976 (1.1)
  Sinusitis                            80 078       45 456 (56.8)                                                       3654 (6.9)                                                                  481 (0.9)    15 282 (28.8)   20 677 (39.0)   11 441 (21.6)   ≤10         779 (1.5)     766 (1.4)
  Bronchitis with COPD                 6832         4313 (63.1)                                                         208 (4.1)                                                                   14 (0.3)     912 (17.8)      2178 (42.5)     1762 (34.3)     28 (0.5)    11 (0.2)      17 (0.3)
  Acne                                 6939         2030 (29.3)                                                         ≤10                                                                         32 (1.5)     174 (8.3)       739 (35.2)      41 (2.0)        ≤10         1050 (50.0)   62 (3.0)
  Non-bacterial GI infections          1215         116 (9.5)                                                           ≤10                                                                         ≤10          42 (33.1)       38 (29.9)       33 (26.0)       ≤10         ≤10           14 (11.0)
  Non-suppurative otitis media         2807         888 (31.6)                                                          63 (5.8)                                                                    ≤10          384 (35.5)      481 (44.5)      128 (11.8)      ≤10         ≤10           26 (2.4)
  Viral URI                            2 74 441     96 989 (35.3)                                                       4839 (4.6)                                                                  825 (0.8)    44 475 (42.1)   37 001 (35.0)   16 941 (16.0)   160 (0.2)   790 (0.7)     601 (0.6)
  Influenza                            22 868       8665 (37.9)                                                         296 (3.1)                                                                   74 (0.8)     3030 (31.9)     3934 (41.5)     2040 (21.5)     ≤10         47 (0.5)      69 (0.7)
  Viral pneumonia                      15           ≤10                                                                 ≤10                                                                         ≤10          ≤10             ≤10             ≤10             ≤10         ≤10           ≤10
  Bronchitis without COPD              89 479       47 248 (52.8)                                                       1509 (3.0)                                                                  332 (0.7)    14 521 (28.5)   22 779 (44.8)   11 078 (21.8)   58 (0.1)    250 (0.5)     346 (0.7)
  Non-infectious diarrhoea             1597         50 (3.1)                                                            ≤10                                                                         ≤10          ≤10             19 (55.9)       15 (44.1)       ≤10         ≤10           ≤10
  Fever                                2908         438 (15.1)                                                          20 (4.3)                                                                    ≤10          190 (40.5)      103 (22.0)      156 (33.3)      ≤10         ≤10           ≤10

\*Antibiotics were coded according to ATC codes: Penicillins, J01C; First-generation cephalosporins, J01DB; Second-generation cephalosporins, J01DC; Third-generation cephalosporins, J01DD; Macrolides, J01FA; Quinolones, J01M; Sulfonamides and trimethoprim, J01E; Tetracyclines, J01A; Other antibiotics, J01B, J01DH, J01DI, J01FF, J01G and J01X.

ATC, Anatomical Therapeutic Chemical; COPD, chronic obstructive pulmonary disease; First/second cephem, first/second-generation cephalosporins; GI infections, gastrointestinal infections; PID, pelvic inflammatory diseases; Skin infections, Skin, cutaneous and mucosal infections; ST, sulfonamides and trimethoprim; STD, sexual transmitted diseases; third cephem, third-generation cephalosporins; URI, upper respiratory infections.

[Table 4](#T4){ref-type="table"} shows the results of the logistic regression analysis of antibiotic prescription for ARTIs. Male sex was associated with more antibiotic prescription (adjusted OR, 1.10; 95% CI, 1.08 to 1.11). With patients aged ≥65 years as reference, patients aged 10--19 years were more likely to be prescribed antibiotics (adjusted OR, 2.75; 95% CI, 2.69 to 2.82), followed by patients aged 20--64 years (adjusted OR, 1.92; 95% CI, 1.89 to 1.94) and patients \<10 years (adjusted OR, 1.48; 95% CI, 1.46 to 1.50). Regarding facility scale, with large-scale (≥500 beds) hospital-based clinics as reference, free-standing clinics (adjusted OR, 4.24; 95% CI, 4.03 to 4.45), small-scale (\<200 beds) hospital-based clinics (adjusted OR, 2.07; 95% CI, 1.97 to 2.18) and medium-scale (200--499 beds) hospital-based clinics (adjusted OR, 1.71; 95% CI, 1.62 to 1.80) were significantly associated with more frequent antibiotic prescription.

###### 

Factors associated with antibiotic prescription for acute upper respiratory infections\*

  Characteristics                              Antibiotic prescription, n (%)   Unadjusted OR (95% CI)   Adjusted OR (95% CI)
  -------------------------------------------- -------------------------------- ------------------------ ----------------------
  Patient age                                                                                            
   0**--**9                                    44 413 (50.4)                    1.66 (1.64 to 1.69)      1.48 (1.46 to 1.50)
   10**--**19                                  20 822 (65.1)                    3.08 (3.00 to 3.15)      2.75 (2.69 to 2.82)
   20**--**64                                  85 952 (54.6)                    1.98 (1.95 to 2.00)      1.92 (1.89 to 1.94)
   ≥65                                         1 21 289 (37.9)                  1                        1
  Patient sex                                                                                            
   Male                                        1 12 643 (47.4)                  1.13 (1.12 to 1.14)      1.10 (1.08 to 1.11)
   Female                                      1 55 038 (44.4)                  1                        1
  Facility scale                                                                                         
   Free-standing clinic                        2 33 078 (49.8)                  4.48 (4.27 to 4.70)      4.24 (4.03 to 4.45)
   Hospital (\<200 beds)-based clinic          23 012 (30.8)                    2.01 (1.91 to 2.11)      2.07 (1.97 to 2.18)
   Hospital (200**--**499 beds)-based clinic   9327 (28.2)                      1.77 (1.68 to 1.89)      1.71 (1.62 to 1.80)
   Hospital (≥500 beds)-based clinic           2064 (18.2)                      1                        1

\*Acute upper respiratory infections include viral upper respiratory infections, pharyngitis, bronchitis and sinusitis.

Similar results were shown with the logistic regression analysis for gastrointestinal infections ([table 5](#T5){ref-type="table"}). Male sex was associated with slightly more antibiotic prescription (adjusted OR, 1.04; 95% CI, 1.01 to 1.06) than the female sex. Patients aged 10--19 years (adjusted OR, 1.92; 95% CI, 1.83 to 2.00), 20--64 years (adjusted OR, 1.55; 95% CI, 1.51 to 1.60) and \<10 years (adjusted OR, 1.76; 95% CI, 1.71 to 1.82) received more antibiotic prescriptions compared with patients aged ≥65 years. With reference to large-scale (≥500 beds) hospital-based clinics, free-standing clinics (adjusted OR, 1.88; 95% CI, 1.68 to 2.10) and small-scale (\<200 beds) hospital-based clinics (adjusted OR, 1.17; 95% CI, 1.04 to 1.32) were associated with frequent antibiotic prescription for gastrointestinal infections.

###### 

Factors associated with antibiotic prescription for gastrointestinal infections

  Characteristics                              Antibiotic prescription, n (%)   Unadjusted OR (95% CI)   Adjusted OR (95% CI)
  -------------------------------------------- -------------------------------- ------------------------ ----------------------
  Patient age                                                                                            
   0**--**9                                    10 809 (37.0)                    1.92 (1.86 to 1.98)      1.76 (1.71 to 1.82)
   10**--**19                                  4395 (38.7)                      2.07 (1.98 to 2.16)      1.92 (1.83 to 2.00)
   20**--**64                                  12 310 (32.4)                    1.57 (1.53 to 1.61)      1.55 (1.51 to 1.60)
   ≥65                                         13 795 (23.4)                    1                        1
  Patient sex                                                                                            
   Male                                        18 547 (30.9)                    1.09 (1.06 to 1.12)      1.04 (1.01 to 1.06)
   Female                                      21 831 (29.1)                    1                        1
  Facility type                                                                                          
   Free-standing clinic                        33 712 (32.9)                    2.03 (1.82 to 2.27)      1.88 (1.68 to 2.10)
   Hospital (\<200 beds)-based clinic          4056 (21.7)                      1.15 (1.02 to 1.29)      1.17 (1.04 to 1.32)
   Hospital (200**--**499 beds)-based clinic   2214 (18.9)                      0.97 (0.86 to 1.09)      0.93 (0.82 to 1.05)
   Hospital (≥500 beds)-based clinic           396 (19.4)                       1                        1

Discussion {#s4}
==========

We described oral antibiotic prescription patterns in the outpatient care setting in Japan. To the best of our knowledge, this is the first Japanese study to comprehensively describe antibiotic prescription patterns linked to individual diagnoses data, using the claims database. Broad-spectrum antibiotics consisting of third-generation cephalosporins, macrolides and quinolones accounted for nearly 90% of antibiotic prescriptions in the primary care settings. Prescription of penicillin was only 5%. This prescription pattern is consistent with the results of an analysis of antibiotic sales data in Japan, in which 77% of oral antibiotics shipped were broad spectrum.[@R7] In contrast, the use of cephalosporins, macrolides and quinolones in the USA and Europe were much lower than in Japan. Hicks *et al* [@R14]analysed the sales data of oral antibiotics in the USA and showed that cephalosporins, macrolides and quinolones accounted for 48% of the total oral antibiotics. In their study, penicillin had the largest share of the antibiotics (23%). Data from the European Surveillance of Antimicrobial Consumption (ESAC) project[@R15] also showed that cephalosporins, macrolides and quinolones accounted for about one-third of the total oral antibiotic consumptions in Europe. This study demonstrated a rather high ratio of broad-spectrum to narrow-spectrum oral antibiotics in Japan; therefore, the quality of antibiotic prescribing needs to be improved.

Although quinolones are not recommended for children, quinolones were prescribed as much as penicillins in children aged 0--9 years in our study. This may be because oral fluoroquinolones such as tosufloxacin are approved for children to treat otitis media and pneumonia in Japan. Since the approval of quinolones in 2010, despite the recommendation to prescribe quinolones carefully for children, many physicians prescribed tosufloxacin to children in expectation of clinical effectiveness.

Among antibiotics linked with individual diagnosis data, \>60% of antibiotics were prescribed for ARTIs, followed by gastrointestinal infections (9%), urinary tract infections (8%) and skin, cutaneous and mucosal infections (5%). Surprisingly, viral URI (common cold) was the most frequent infection associated with antibiotic prescription. In the ambulatory care setting in the USA, antibiotics were prescribed most frequently for acute respiratory conditions (41%--44%), followed by skin and mucosal conditions (15%--19%), urinary tract infections (7%--8%) and gastrointestinal conditions (5%--6%).[@R13] Another study using primary care data in the UK[@R17] demonstrated that 46% of antibiotics were prescribed for respiratory tract conditions, followed by urogenital tract (23%) and skin conditions (10%). Only 1% was prescribed for gastrointestinal conditions. Our study demonstrated a higher proportion of antibiotic prescription for ARTIs (approximately 15% higher than those in USA or UK) and gastrointestinal infections (approximately 5% higher) in Japan.

Antibiotics were prescribed for 35% of viral URI cases and approximately 50%--60% of pharyngitis, bronchitis and sinusitis cases in our study. These prescription rates were approximately similar to those of a USA study,[@R13] which showed a rate of 30% for viral URI, 62% for pharyngitis, 65% for bronchitis and 72% for sinusitis. Medically, antibiotics are rarely indicated for ARTIs.[@R18] Antibiotics have no role in the treatment of either viral URI (common cold) or the majority of acute bronchitis cases, which are generally caused by viral infection. Only a minority of patients with bronchitis (\<10%), for example, patients who have underlying COPD or whooping cough, may derive any benefit from antibiotic treatment. With pharyngitis, antibiotics are mainly indicated only for streptococcal pharyngitis, which accounts for 5%--15% of pharyngitis in adults and 20%--30% in children.[@R19]

The antibiotic prescription rate for gastrointestinal infections was three times higher than the rate reported in the USA (30% vs 10%).[@R13] As most acute gastroenteritis is self-limiting, the Japanese national guideline recommends the non-usage of antibiotics for gastroenteritis unless symptoms are severe.[@R10] Based on our study, approximately 70% of oral antibiotics are prescribed for ARTIs or acute gastroenteritis; however, most (\>80%) did not require antibiotics. Therefore, there is a need for suitable targets to reduce unnecessary antibiotic use in accordance with antimicrobial stewardship programme. Previous studies from the UK[@R21] analysed reasons for antibiotic prescribing for sore throats and assessed that patient demand for antibiotics and physician pressure to meet patient demand are associated with antibiotic prescription. In addition, we suppose that physicians frequently prescribe antibiotics for URI as prophylaxis for complicating secondary bacterial infections. Previous qualitative studies identified that additional factors associated with antibiotic prescription included diagnostic uncertainty, unawareness of guidelines, time pressure at work, and patient expectations regarding antibiotics.[@R23]

As for antibiotic prescription for ARTIs and gastrointestinal infections, most antibiotics prescribed were broad spectrum. For example, quinolones accounted for 15%--35% of the antibiotics prescribed for ARTIs in this study, although the proportion of quinolones to whole antibiotics prescribed for ARTIs should be \<5% according to the ESAC disease-specific quality indicators.[@R26] Accordingly, the quality of antibiotic prescribing should be improved.

The logistic regression analyses revealed several factors associated with antibiotic prescriptions for ARTIs and gastrointestinal infections. The smaller the facility scale, the higher the odds of antibiotic prescribing. Recent studies from Japan[@R8] and Taiwan[@R27] have found similar results. As family practitioners, paediatricians, and internists usually prescribe a high number of antibiotic courses,[@R14] greater adherence to treatment guidelines among physicians in these specialties is particularly important. It has also been reported that mid-career or late-career stage physicians (because the effect of training received during medical education might have reduced after this long time) were more likely to prescribe antibiotics for non-bacterial acute URI.[@R28]

Patient age was another factor associated with antibiotic prescription. In this study, antibiotic prescription rates for ARTIs and gastrointestinal infections were highest in patients aged 10--19 years, followed by patients aged 20--64 years (ARTIs) or 0--9 years (gastrointestinal infections). A previous study concerning Dutch primary care showed similar results of antibiotic overprescribing for ARTIs in patients aged 31--65 years (ie, not in children or the elderly).[@R29] As adolescents and young adults generally pose a much lower risk of disease complications than young children or elderly individuals, antimicrobial stewardship should focus on these age groups of patients. In this study, male sex was also associated with increased antibiotic prescribing. Although a patient sex difference was observed in another study, the results differed; female patients were more likely to have high prescribing in the USA.[@R14] The reason for patient age and sex difference in antibiotic prescribing remains to be clarified. Patient sex and age-standardised antibiotic prescription rates need to be assessed in Japan for effective intervention.

Our study has several limitations. First, our results do not represent the entire antibiotic prescription pattern in Japan because the claims database used in this study was composed of claims in only one prefecture. Geographical diversity in antibiotic prescribing may be present, as observed in the previous study from the USA.[@R14] Second, since we used an administrative claims database, the accuracy of the diagnosis was not validated. In addition, we could not link diagnosis and antibiotic prescriptions on a one-to-one level when patients had multiple infectious diagnoses. Third, there may be other potential confounding factors that were not included in this study. For example, information on out-of-hours visits,[@R8] non-specialty physicians[@R8] and patient's low per capita income or low education,[@R14] which have been reported as potential factors associated with inappropriate antibiotics prescribing, could not be extracted from the claims database in this study. Fourth, only 65% of antibiotic prescriptions were linked to infectious disease visits. This may be partly because we could not capture the information concerning follow-up visits when patients had multiple visits for a single infection (antibiotics were linked to the infectious diagnoses only when they were prescribed at the first visit of an illness episode). In addition, approximately 3%--5% of medical claims that included diagnostic codes and 0.1% of pharmacy claims that included prescription (medication) codes were registered in non-digital format. As non-digital insurance claims were not included in our database, 3%--5% of antibiotic prescriptions were not linked to diagnoses. Therefore, inappropriate antibiotic prescription might be underestimated rather than overestimated.

In conclusion, this Japanese study demonstrated that third-generation cephalosporins, macrolides and quinolones accounted for 88% of oral antibiotic prescription. Approximately 60% of antibiotic prescription was provided for ARTIs, with viral URI and pharyngitis being the two ARTI diagnoses with the largest antibiotic prescriptions. Gastrointestinal infections were the second most common diagnosis for antibiotic prescribing. The scale of the facilities (clinic or small-scale hospital) and patient age (adolescents and young adults) were factors associated with antibiotic overprescription. Antimicrobial stewardship interventions should focus on targeting antibiotic prescribing for these infectious diagnoses, patients and institutions. Further nationwide studies are needed to support our data, and longitudinal studies using medical claims data are needed to evaluate the effectiveness of antimicrobial stewardship.
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